RhumbLine Advisers
SKYE icon

RhumbLine Advisers’s Skye Bioscience SKYE Stock Holding History

RhumbLine Advisers’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,423
Closed -$22.9K – 4291
2025
Q1 		$22.9K Sell
14,423
-3,082
-18% -$8.41K ﹤0.01% 3718
2024
Q4 		$49.5K Buy
17,505
+664
+4% +$2.77K ﹤0.01% 3651
2024
Q3 		$65.8K Sell
16,841
-2,913
-15% -$16.3K ﹤0.01% 3629
2024
Q2 		$158K Buy
+19,754
New +$234K ﹤0.01% 3355

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RhumbLine Advisers's SKYE Position: Q2 2025 in Review

RhumbLine Advisers sold out of Skye Bioscience (SKYE) in Q2 2025, closing a stake of 14,423 shares — an estimated $22.9K sold.

RhumbLine Advisers first reported a position in SKYE in Q2 2024 and held it in 4 quarters. The position peaked at $158K in Q2 2024. 58 funds tracked by Wall St. Rank hold SKYE as of Q2 2025.

  • RhumbLine Advisers reported no remaining Skye Bioscience position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 14,423 Skye Bioscience shares in Q2 2025, an estimated $22.9K.
  • RhumbLine Advisers first reported a position in Skye Bioscience in Q2 2024 and held it in 4 quarters.
  • RhumbLine Advisers's Skye Bioscience position peaked at $158K in Q2 2024.
  • 58 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.